Re: Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 Guideline-Reference-Cited by-同舟云学术

Re: Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 Guideline

Published:2023-12 Issue:6 Volume:6 Page:635-636
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Gandaglia Giorgio,Briganti Alberto,Chiti Arturo,Cozzarini Cesare,Montorsi Francesco

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference7 articles.

1. Prostate-specific membrane antigen positron emission tomography/computed tomography–based lymph node atlas for salvage radiotherapy in patients with recurrent prostate cancer: a validation of the new NRG Oncology 2020 guideline;Vogel;Eur Urol Oncol,2022

2. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur Urol,2021

3. Tilki D, Chen M-H, Wu J, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.02489.

4. [68Ga]Ga-PSMA versus [18F]PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. a systematic review of the literature;Evangelista;Eur Urol Oncol,2022

5. Bukavina L, Luckenbaugh AN, Hofman MS, et al. Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.024.